SEP 06, 2018 11:00 PM PDT

First FDA Approved Drug Derived From Marijuana Used to Treat Two Rare Forms of Epilepsy

WRITTEN BY: Amanda Kahl

The FDA (Food and Drug Administration) approved the first oral cannabidiol solution called Epidiolex in June of 2018. This medicine was approved as a treatment for two forms of severe drug-resistant epilepsy. This is the first time that the federal government has approved a medication derived directly from the cannabis plant. 

LGS (Lennox-Gastaut Syndrome) and DS (Dravet Syndrome) are two rare and severe forms of epilepsy with onset in early childhood. "The syndromes are categorized as developmental and epileptic encephalopathies, in which the epileptic activity is thought to contribute to developmental delay and behavioral abnormalities beyond the pathology of the underlying disease," stated Teresa Buracchio, who is the Clinical Team Leader from the Division of Neurology Products at the FDA. These forms of refractory epilepsy syndromes are resistant to drugs that are typically used for the treatment of seizures. Buracchio further explains that "Both syndromes are associated with higher rates of mortality than in the general epilepsy population, primarily due to status epilepticus and sudden unexpected death in epilepsy patients." 

The FDA conducted three randomized, double-blind, placebo-controlled trials with patients who have LGS and DS. The results from the study performed with 225 patients with LGS showed significant improvement with the use of CBD, "The median number of "drop seizures" (which can cause falls) during a 28-day period fell from 85.5 to 44.9 in the high-dose group (a decrease of 49 percent), from 86.9 to 50 in the low-dose group (43 percent), and from 80.3 to 72.7 in the placebo group (21 percent)." In the study that was performed with 120 patients with DS also showed significant improvement with the use of CBD, "The median number of convulsive seizures over 28 days fell from 12.4 to 5.9 in the CBD group (a drop of 52 percent) and from 14.9 to 14.1 in the placebo group (5 percent)."

Epidiolex contains CBD, which is a cannabinoid found within the marijuana plant. It is known that cannabinoids interact with a multitude of neurotransmitters and neuromodulator systems and have the ability to interact with cellular pathways. By acting as ligands, they are able to modulate a receptor's behavior and their downstream biological pathways. According to GW Pharmaceuticals (the company that created the drug), CBD produces an anticonvulsant effect, it does this by, "...modulating a number of endogenous systems including, but not limited to neuronal inhibition (synaptic and extrasynaptic GABA channels, modulation of intracellular calcium (TRPV, VDAC, GPR55), and possible anti-inflammatory effects."

Both forms of seizures are difficult to control and with the treatment option of CBD for patients diagnosed it can dramatically improve their quality of life. The use of medical marijuana is approved in 30 states and Washington D.C., 25 out of these 30 states specifically recognize epilepsy as a qualifying condition. These states allow treatment of epilepsy with low dose THC or high dose CBD oil and are now making it easier to legally obtain the drug Epidiolex. The creation of this drug and its approval are a huge step in offering patients a safe, controlled, and tested medication. 

Sources: ReasonFDA Briefing DocumentGWPharm Mechanism of Action

About the Author
  • Amanda has a Bachelor's in Biological Sciences from the University of Cincinnati. She has a passion for animals, conservation, and environmental sciences. Through her career in science and research, she is able to develop her passion and hopes to pass on to others the joy of learning about science.
You May Also Like
SEP 20, 2019
Health & Medicine
SEP 20, 2019
Use of Highly Potent Marijuana Could Pose Risks for Adolecents
A 2018 biennial survey given to secondary school students in Arizona shows that one third of students in that age range have tried some form of marijuana,...
SEP 20, 2019
Cannabis Sciences
SEP 20, 2019
Will Cannabis Facilities Pollute the Air?
The strong smell of cannabis comes from chemicals that could potentially cause indoor or outdoor air pollution, if not properly managed, a new study finds....
OCT 09, 2019
Cannabis Sciences
OCT 09, 2019
Cannabidiol's Role in Psychiatry
How can health professionals in the clinical psychiatry field make sense of cannabis products boasting various health claims? One professor’s present...
OCT 25, 2019
Cannabis Sciences
OCT 25, 2019
U.S.A. Triathlon Makes Landmark Sponsorship Deal with CBD Company
U.S.A. Triathlon has just made a sponsorship deal with a company selling CBD products. This is a first for national governing bodies. Athletes, who often a...
NOV 22, 2019
Health & Medicine
NOV 22, 2019
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
JAN 04, 2020
Cannabis Sciences
JAN 04, 2020
How Not to Get Arrested when Traveling with Medical Marijuana
As 33 states in the US have legalized some form of medical marijuana, one might assume that traveling with it should be relatively hassle-free. But differe...
Loading Comments...